Urothelial cancer approval for Gemzar in Japan
This article was originally published in Scrip
Executive Summary
Lilly's chemotherapy Gemzar (gemcitabine) has been approved in Japan for the additional indication of urothelial cancer. The product is already approved in this market for non-small cell lung, pancreatic and biliary tract cancers and is in local development for breast cancer. Urothelial cancer affects an estimated 16,000 people in the country, mostly older men, the company's Japanese subsidiary noted. Total sales of Gemzar in Japan last year were around ¥15 billion ($157.7 million).
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.